Literature DB >> 7593136

Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB4.

Y Hashimoto1, H Kagechika, E Kawachi, H Fukasawa, G Saito, K Shudo.   

Abstract

Retinoids, including all-trans-retinoic acid, its isomers, and fifty synthetic retinoids (retinobenzoic acids), were tested for differentiation-inducing activity on human leukemia cell lines HL-60 and NB4. A good linear correlation, with an r value of 0.91, between the ED50 values for the differentiation-inducing activity towards HL-60 cells and that towards NB4 cells was found.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7593136     DOI： 10.1007/BF01218530

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  15 in total

1.  Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture.

Authors:  S J Collins; R C Gallo; R E Gallagher
Journal:  Nature       Date:  1977-11-24       Impact factor: 49.962

2.  A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein.

Authors:  J A Dyck; G G Maul; W H Miller; J D Chen; A Kakizuka; R M Evans
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

3.  Retinobenzoic acids. 2. Structure-activity relationships of chalcone-4-carboxylic acids and flavone-4'-carboxylic acids.

Authors:  H Kagechika; E Kawachi; Y Hashimoto; K Shudo
Journal:  J Med Chem       Date:  1989-04       Impact factor: 7.446

4.  RAR-alpha gene rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia.

Authors:  A Biondi; A Rambaldi; M Alcalay; P P Pandolfi; F Lo Coco; D Diverio; V Rossi; A Mencarelli; L Longo; D Zangrilli
Journal:  Blood       Date:  1991-04-01       Impact factor: 22.113

5.  Remission induction of acute promyelocytic leukemia by all-trans-retinoic acid: molecular evidence of restoration of normal hematopoiesis after differentiation and subsequent extinction of leukemic clone.

Authors:  H Ohashi; A Ichikawa; N Takagi; T Hotta; T Naoe; R Ohno; H Saito
Journal:  Leukemia       Date:  1992-08       Impact factor: 11.528

6.  Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity.

Authors:  H Kagechika; E Kawachi; Y Hashimoto; T Himi; K Shudo
Journal:  J Med Chem       Date:  1988-11       Impact factor: 7.446

7.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

Authors:  M E Huang; Y C Ye; S R Chen; J R Chai; J X Lu; L Zhoa; L J Gu; Z Y Wang
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

8.  HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3.

Authors:  W T Dalton; M J Ahearn; K B McCredie; E J Freireich; S A Stass; J M Trujillo
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

9.  Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid.

Authors:  T R Breitman; S E Selonick; S J Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

10.  NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3).

Authors:  M Lanotte; V Martin-Thouvenin; S Najman; P Balerini; F Valensi; R Berger
Journal:  Blood       Date:  1991-03-01       Impact factor: 22.113
View more
  10 in total

Review 1.  Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.

Authors:  Hisham Abdel-Azim; Weili Sun; Lingtao Wu
Journal:  Pharmacol Ther       Date:  2019-08-27       Impact factor: 12.310

2.  Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.

Authors:  David Sanford; Francesco Lo-Coco; Miguel A Sanz; Eros Di Bona; Steven Coutre; Jessica K Altman; Meir Wetzler; Steven L Allen; Farhad Ravandi; Hagop Kantarjian; Jorge E Cortes
Journal:  Br J Haematol       Date:  2015-07-24       Impact factor: 6.998

Review 3.  Treatment for relapsed acute promyelocytic leukemia.

Authors:  Masamitsu Yanada
Journal:  Ann Hematol       Date:  2022-08-16       Impact factor: 4.030

4.  Retinoid agonist Am80-enhanced neutrophil bactericidal activity arising from granulopoiesis in vitro and in a neutropenic mouse model.

Authors:  Wanjing Ding; Hiroyuki Shimada; Lin Li; Rahul Mittal; Xiaokun Zhang; Koichi Shudo; Qiaojun He; Nemani V Prasadarao; Lingtao Wu
Journal:  Blood       Date:  2012-12-13       Impact factor: 22.113

Review 5.  Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.

Authors:  Akihiro Tomita; Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2013-05-14       Impact factor: 2.490

Review 6.  PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.

Authors:  Kazunori Ohnishi
Journal:  Int J Clin Oncol       Date:  2007-10-22       Impact factor: 3.402

Review 7.  Current first- and second-line treatment options in acute promyelocytic leukemia.

Authors:  Fulvio Massaro; Matteo Molica; Massimo Breccia
Journal:  Int J Hematol Oncol       Date:  2017-02-02

Review 8.  Acute promyelocytic leukemia: where did we start, where are we now, and the future.

Authors:  C C Coombs; M Tavakkoli; M S Tallman
Journal:  Blood Cancer J       Date:  2015-04-17       Impact factor: 11.037

9.  Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene: A case report.

Authors:  Minoru Kojima; Daisuke Ogiya; Akifumi Ichiki; Ryujiro Hara; Jun Amaki; Hidetsugu Kawai; Hiroki Numata; Ai Sato; Mitsuki Miyamoto; Rikio Suzuki; Shinichiro Machida; Hiromichi Matsushita; Yoshiaki Ogawa; Hiroshi Kawada; Kiyoshi Ando
Journal:  Leuk Res Rep       Date:  2016-01-22

10.  A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML.

Authors:  Alexander J Ambinder; Kelly Norsworthy; Daniela Hernandez; Laura Palau; Bogdan Paun; Amy Duffield; Rosh Chandraratna; Martin Sanders; Ravi Varadhan; Richard J Jones; B Douglas Smith; Gabriel Ghiaur
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.